Cepheid announced that it has received clearance from the FDA to market Xpert CT/NG, an in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). These are the two most common sexually transmitted bacterial infections in the U.S.
This new test enables clinicians to give same-day patient consultation and treatment by obtaining test results within 90 minutes. Xpert CT/NG incorporates several novel features: an in silico approach that uncovers multiple genomic targets for improving accuracy of both CT and NG detection, and a sample adequacy control that adds to the interpretation of diagnostic results generated by the GeneXpert System. The GeneXpert system combines on-board sample preparation with real-time PCR amplification and detection functions for fully integrated and automated nucleic acid synthesis.
Xpert CT/NG will begin shipping in January.
For more information call (408) 541-4191 or visit www.cepheid.com.